drugset / Trial / NCT00142155

Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia

NCT00142155

Completed 300 enrolled Dana-Farber Cancer Institute

Summary

The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodies.

Timeline

Start
2002-01
Primary completion
2007-03
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody